NO20012128L - DDS-forbindelse og metode for måling av denne - Google Patents

DDS-forbindelse og metode for måling av denne

Info

Publication number
NO20012128L
NO20012128L NO20012128A NO20012128A NO20012128L NO 20012128 L NO20012128 L NO 20012128L NO 20012128 A NO20012128 A NO 20012128A NO 20012128 A NO20012128 A NO 20012128A NO 20012128 L NO20012128 L NO 20012128L
Authority
NO
Norway
Prior art keywords
measuring
dds
connection
dds connection
Prior art date
Application number
NO20012128A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012128D0 (no
Inventor
Hiroshi Susaki
Kazuhiro Inoue
Hiroshi Kuga
Masahiro Ikeda
Yoshinobu Shiose
Hiroshi Korenaga
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO20012128D0 publication Critical patent/NO20012128D0/no
Publication of NO20012128L publication Critical patent/NO20012128L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO20012128A 1998-10-30 2001-04-30 DDS-forbindelse og metode for måling av denne NO20012128L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31013098 1998-10-30
JP32927298 1998-11-19
PCT/JP1999/006016 WO2000025825A1 (fr) 1998-10-30 1999-10-29 Composes dds et procede de dosage de ces composes

Publications (2)

Publication Number Publication Date
NO20012128D0 NO20012128D0 (no) 2001-04-30
NO20012128L true NO20012128L (no) 2001-06-20

Family

ID=26566202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012128A NO20012128L (no) 1998-10-30 2001-04-30 DDS-forbindelse og metode for måling av denne

Country Status (15)

Country Link
US (2) US6811996B1 (fr)
EP (2) EP1155702A4 (fr)
KR (1) KR20010090602A (fr)
CN (2) CN1191093C (fr)
AU (1) AU765409B2 (fr)
BR (1) BR9915198A (fr)
CA (1) CA2348931A1 (fr)
EA (1) EA003790B1 (fr)
HK (1) HK1042438A1 (fr)
ID (1) ID29943A (fr)
IL (1) IL142842A0 (fr)
MX (1) MXPA01004239A (fr)
NO (1) NO20012128L (fr)
TW (1) TWI232930B (fr)
WO (1) WO2000025825A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
WO1999061061A1 (fr) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
MXPA01004239A (es) * 1998-10-30 2002-06-04 Daiichi Seiyaku Co Compuesto dds y metodo para la medicion del mismo.
BR0112287A (pt) * 2000-06-29 2003-05-06 Daiichi Seiyaku Co Composto dds e seu método de preparação
US7456265B2 (en) * 2004-05-10 2008-11-25 Board Of Trustees Of Michigan State University Carboxylated polysaccharides and method of preparation and use
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
EP1926498A2 (fr) * 2005-09-22 2008-06-04 Hadasit Medical Research Services And Development Company Ltd. Conjugues de compose a activite therapeutique
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (fr) 2010-05-25 2011-12-01 Syndevrx, Inc. Inhibiteurs des metap2 conjugués à des polymères et leurs méthodes d'utilisation dans le domaine thérapeutique
TW201348244A (zh) * 2012-05-23 2013-12-01 Iner Aec Executive Yuan 醣質藥物造影劑前驅物之合成方法
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (fr) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
EP3574922B1 (fr) 2013-04-10 2021-09-15 Syndevrx, Inc. Inhibiteurs de fumagillol metap2 modifiés ou conjugués par un polymère destinés à être utilisés dans l'amélioration ou la restauration de la sensibilite de l'insuline
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) * 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
US12685781B2 (en) 2014-04-10 2026-07-21 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
CA2990572C (fr) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Procede pour la preparation selective d'un conjugue anticorps-medicament
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
JOP20170057B1 (ar) * 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018066626A1 (fr) 2016-10-07 2018-04-12 第一三共株式会社 Traitement contre le cancer pharmacorésistant par administration d'un conjugué anticorps anti-her2/médicament
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3677589B1 (fr) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Procédé amélioré de production d'un conjugué anticorps-médicament
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3794042B1 (fr) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Konjugierter zytotoxischer mittel und antikörper anti-muc1-exatecan
EP3831853A4 (fr) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited Protéine reconnaissant la fraction médicamenteuse d'un conjugué anticorps-médicament
IL325918A (en) 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
CN118047886A (zh) * 2022-11-17 2024-05-17 菲鹏生物股份有限公司 化合物及其制备方法和封闭剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
JP2791001B2 (ja) 1990-02-16 1998-08-27 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
DK0526649T3 (da) 1991-02-21 1998-10-07 Drug Delivery System Inst Ltd Carboxymethylmannoglucan og derivater deraf.
JP2589431B2 (ja) 1991-05-13 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリグルタミン酸誘導体及びその製造法
JP2774417B2 (ja) 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー
JP2589435B2 (ja) 1991-09-17 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリリジン誘導体
JP2774429B2 (ja) 1992-03-17 1998-07-09 株式会社ディ・ディ・エス研究所 糖骨格を有する分枝鎖型誘導体
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
JP2610792B2 (ja) 1993-02-26 1997-05-14 株式会社ディ・ディ・エス研究所 多糖誘導体および薬物担体
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
GB2282384B8 (en) 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
JP3418693B2 (ja) 1993-09-06 2003-06-23 敏宏 赤池 ポリ−ε−置換−L−リジンのD−ガラクトピラノシル−グルコン酸誘導体
JPH07228688A (ja) 1994-02-18 1995-08-29 Yamanouchi Pharmaceut Co Ltd 糖修飾ポリ−ω−置換−L−グルタミン酸誘導体およびその製造方法
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
JP3001381B2 (ja) 1994-09-16 2000-01-24 株式会社ディ・ディ・エス研究所 臓器移行性を有する多糖誘導体および薬物担体
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
JP3053764B2 (ja) 1995-03-17 2000-06-19 財団法人神奈川科学技術アカデミー 糖鎖高分子及びそれを用いた細胞処理剤並びに処理方法
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
CA2182851A1 (fr) * 1995-08-15 1997-02-16 August Masaru Watanabe Methode de traitement d'un etat resultant de l'arret de la consommation abusive de drogues
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
EP0941120A4 (fr) * 1996-11-05 2004-08-18 Bristol Myers Squibb Co Sequences de liaison peptidiques ramifiees
WO1998026747A2 (fr) * 1996-12-17 1998-06-25 Terman David S Procedes et compositions de traitement de maladies a base de superantigenes
JP2002508758A (ja) 1997-06-12 2002-03-19 エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー 生物的に活性な材料
WO1999061061A1 (fr) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
MXPA01004239A (es) * 1998-10-30 2002-06-04 Daiichi Seiyaku Co Compuesto dds y metodo para la medicion del mismo.

Also Published As

Publication number Publication date
BR9915198A (pt) 2001-08-14
ID29943A (id) 2001-10-25
WO2000025825A1 (fr) 2000-05-11
NO20012128D0 (no) 2001-04-30
AU6488099A (en) 2000-05-22
CN1661044A (zh) 2005-08-31
US6811996B1 (en) 2004-11-02
MXPA01004239A (es) 2002-06-04
CN1191093C (zh) 2005-03-02
US7041818B2 (en) 2006-05-09
EA003790B1 (ru) 2003-10-30
EA200100485A1 (ru) 2001-12-24
CA2348931A1 (fr) 2000-05-11
TWI232930B (en) 2005-05-21
EP1155702A1 (fr) 2001-11-21
EP1619210A1 (fr) 2006-01-25
IL142842A0 (en) 2002-03-10
EP1155702A4 (fr) 2004-12-15
CN1332640A (zh) 2002-01-23
HK1042438A1 (zh) 2002-08-16
KR20010090602A (ko) 2001-10-18
AU765409B2 (en) 2003-09-18
US20040192644A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20012128D0 (no) DDS-forbindelse og metode for måling av denne
NO992351D0 (no) Pµl og fremgangsmÕte for installasjon av denne
NO983366L (no) FremgangsmÕte og anordning for bestemmelse av banen til borehull
NO980605D0 (no) Fremgangsmåter og anordning for komplettering av underjordisk brönn
NO980604D0 (no) Fremgangsmåte og anordning for komplettering av en underjordisk brönn
NO980603D0 (no) Fremgangsmåte og anordning for komplettering av en underjordisk brönn
NO980602D0 (no) Fremgangsmåte og anordning for komplettering av en underjordisk brönn
NO980591D0 (no) Fremgangsmåte og anordning for komplettering av en underjordisk brönn
NO20010994D0 (no) FremgangsmÕte og innretning for bestemmelse av beskaffenheten av underjordiske reservoarer
NO983278L (no) System for inspeksjon og evaluering av utstyr, system for administrering av
NO973266D0 (no) Anordning for komplettering av en underjordisk brönn og tilhörende fremgangsmåte
EE200000480A (et) Seade ja meetod manustamise toimumise indikatsiooniks
NO984753L (no) FremgangsmÕte for mÕling og system omfattende en halvstiv forlengelse
FI981133A0 (fi) Mittausmenetelmä ja -järjestelmä
IT1285935B1 (it) Metodo e dispositivo per il controllo dell'integrita' esteriore di sigarette
NO995324L (no) Baerer for gjenstander og emne for denne
NO330986B1 (no) Fremgangsmate for bestemmelse av seismisk polaranisotropi
NO953527D0 (no) Petrofysisk måleanordning og fremgangsmåte for bruk av denne
ID21818A (id) Metode verifikasi lokasi deret detektor
ID27483A (id) Metoda terapi gen
FI980724L (fi) Aikaeron mittausmenetelmä ja radiojärjestelmä
NO991577D0 (no) FremgangsmÕte og system for testing av borehull
NO982074D0 (no) FremgangsmÕte og instrument for nivÕmÕling
FI981029L (fi) Menetelmä ja järjestely testaukseen
FI981431A7 (fi) Mittausmenetelmä

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application